Truist raised the firm's price target on Encompass Health to $108 from $104 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results for Healthcare Services. The firm remains bullish on the sector's fundamental drivers, including attractive core demand trends and relative positioning, the analyst tells investors in a research note. Investors are likely to largely look through the transient impact from adverse weather conditions and supply chain disruptions, focusing on the sector's strong free cash flow, abundant M&A opportunities across verticals, and a backdrop for significant growth opportunity from brisk tailwinds that include demographics and value-based care, the firm added.